Evidence map›Paper›PMID 38388916›Full record

ArticleGeroScience2024

Age associated susceptibility to SARS-CoV-2 infection in the K18-hACE2 transgenic mouse model.

Varun Dwivedi, Vinay Shivanna, Shalini Gautam, Jennifer Delgado, Amberlee Hicks, Marco Argonza, Reagan Meredith, Joanne Turner, Luis Martinez-Sobrido, Jordi B Torrelles and 1 more

Open access · greenAbstract read
In one paragraph

Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Varun DwivediDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Vinay ShivannaPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Shalini GautamPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Jennifer DelgadoDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Amberlee HicksDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Marco ArgonzaDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Reagan MeredithDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Joanne TurnerHost Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. joanneturner@txbiomed.org.
Luis Martinez-SobridoDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. lmartinez@txbiomed.org.
Jordi B TorrellesPopulation Health Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. jtorrelles@txbiomed.org.ORCID 0000-0001-7702-5941
Viraj KulkarniDisease Intervention & Prevention Program, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. vkulkarni@txbiomed.org.ORCID 0000-0002-2094-360X
Texas Biomedical Research Institute · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Social stress as a co-morbidity of age-associated tuberculosisP01AG051428 · NIA · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2016 to 2020
$9.9M
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)P30AI168439 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI JOANNE TURNER · 2022 to 2026
$6.9M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
NIAID NIH HHS P30 AI168439NIAID NIH HHS R01 AI161175NIA NIH HHS P01 AG051428NIH HHS P51 OD011133NINR NIH HHS 3P01-AG-051428-05S1
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still an ongoing global health crisis. Clinical data indicate that the case fatality rate (CFR) is age dependent, with a higher CFR percentage in the elderly population. We compared the pathogenesis of SARS-CoV-2 in young and aged K18-hACE2 transgenic mice. We evaluated morbidity, mortality, viral titers, immune responses, and histopathology in SARS-CoV-2-infected young and old K18-hACE2 transgenic mice. Within the limitation of having a low number of mice per group, our results indicate that SARS-CoV-2 infection resulted in slightly higher morbidity, mortality, and viral replication in the lungs of old mice, which was associated with an impaired IgM response and altered cytokine and chemokine profiles. Results of this study increase our understanding of SARS-CoV-2 infectivity and immuno-pathogenesis in the elderly population.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2AgedAnimalsCytokinesDisease Models, AnimalHumansImmunoglobulin MMiceMice, TransgenicACE2 protein, humanAngiotensin-Converting Enzyme 2CytokinesImmunoglobulin MAgingCOVID-19Cytokine stormK18-hACE2 transgenic mouseSARS-CoV-2 infection

Identifiers

PMID38388916
PMCPMC11009211
OpenAlexW4392024422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.